Recently, the three-day 2024 CPHI Milan exhibition concluded successfully in Milan, Italy. As a leading global platform for showcasing the most advanced development of pharmaceutical industry , the event attracted numerous international pharmaceutical and biopharmaceutical companies. Porton Pharma Solutions, one of the leaders in China's CDMO industry, made another impressive appearance at the event. With its end-to-end CDMO service capabilities in the fields of small molecules, peptides and oligonucleotides, biologics and conjugates, Porton seized this opportunity to share the latest industry insights and discuss future challenges with industry peers, demonstrating its determination and perseverance in steadily advancing its globalization strategy. Company leaders and teams of global marketing professionals and scientists were present on-site to engage in in-depth exchanges with the attendees.



On the second day of the exhibition, Porton hosted two industry seminars at its booth 5C17, delving into hot topics and development trends in the pharmaceutical industry. These sessions attracted attendees who actively engaged in the discussions. During the first seminar, Dr. FrancescoFontana, R&D Director at Porton Pharmatech Slovenia, delivered a presentation titled "Porton Slovenia Capabilities: Driving Innovation and Excellence in the CDMO Industry" . He provided an in-depth overview of Porton Slovenia's operations and its development plans. As Porton’s first R&D and production base in Europe, we are bringing new development, growth, and innovation opportunities to the local industry while also better meeting the growing customer demand for global secure supply chains and high-quality, innovative, and reliable CDMO services.

Link to website news: Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia-News -PORTON





Subsequently, Dr. Jian Wang, head of Porton's Global Chemical Engineering and Technology Center, shared insights and experiences focusing on "Integrated DS-DP Development via Particle Engineering" .Those industry seminars not only strengthened Porton's relationships with global customers and partners but also provided more ideas and directions for the company's future development.



Porton is dedicated to providing high-quality, efficient, and safe pharmaceutical products and end -to-end services to patients worldwide and our services cover the entire drug development lifecycle, ranging from OEB 1 to OEB 5, from gram-scale to ton-scale, and from preclinical to commercial stages. By the middle of 2024, we had successfully delivered over 3,500 projects, serving more than a thousand clients worldwide. It boasts a R&D team of over 1,200 professionals spread across China, the US, and Europe. During this exhibition, Porton hosted several client meetings to share the latest advancements in new drug and new modalities R&D and manufacturing, system optimization and upgrading, as well as global supply chain security. Clients expressed that the exchanges gave them a deeper insight into industry trends and Porton's innovative practices, and they are confident about future collaborations.



Porton remains committed to its core values by prioritizing clients and striving for excellence, driving sustainable development through innovation. We provide exceptional end-to-end CDMO services for pharmaceutical companies, new drug development institutions, and research institutes. Whether for small molecule, Tides, biologicals and conjugated drugs, we offer flexible supply chain solutions in China, the United States, and Europe to meet diverse client needs.



Looking to the future, our focus is on building robust CDMO capabilities for drug development and continually strengthening our core competitiveness. We will continue to uphold our corporate mission of "Enabling the public’s earlier access to good medicines" by seizing opportunities within the global pharmaceutical industry. By collaborating with international pharmaceutical partners and continuously pursuing technological and industrial advancements, we aim to enhance our integrated services from drug substance (DS) to drug product (DP), encompassing both traditional medicines and new modalities.

Driving innovation and excellence in the CDMO industry, Porton looks forward to seeing you again in Frankfurt, Germany, in 2025!